DrugDashboards

lisdexamfetamine dimesylate

lisdexamfetamine dimesylate · LISDEXAMFETAMINE DIMESYLATE 40 mg/1 · Capsule · Oral · Alvogen Inc.

NDC 47781-0565-01 · 100 CAPSULE in 1 BOTTLE · ANDA · View full market →

The short version

6 companies supply this market — a reasonable cushion if one runs into trouble. The generic price has fallen 33% in a year, to $2.63 per unit — and generics that get this cheap tend to get abandoned rather than defended. The brand (Vyvanse) runs $12.35 per unit — 4.6× more. It is in shortage right now — FDA lists the reason as “shortage of an active ingredient”. Put together: worth watching — several of the pressures that precede supply trouble are present at once.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$2.63per EAinvoice-surveyed acquisition cost · Aug 19, 2026
  • Part D plans paid (avg)$6.94per dosage unitgross, before rebates — matched by drug name · 2024
  • Medicaid generic ceiling (FUL)$2.63per CAPweighted avg manufacturer price $1.1615 · Aug 1, 2026100% of what pharmacies pay — higher than 10% of drugs with this benchmark

Medicare Part D

All Part D pricing →

Matched to CMS's representative package for this drug (NDC 00527-4664-37) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of saleⓘ
$5.51per unit
middle half $4.39–$5.89 · 2,437 plans · Apr 1, 2026
Est. net of rebatesⓘ
≈ $5.51
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
44%of plans cover it
tier 4 · prior auth 11% · step therapy 1% · qty limit 59%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

$0$2.50$5.00$7.50Oct 2023Sep 2026$2.63
36 price points · per EA · dashed = manufacturer avg (WAMP)Source: CMS NADAC

Estimated fill cost

#30 count
$78.89
#90 count
$236.68

Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.

Medicaid spend (2025)

$6.2M
50,977 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

41● Elevated risk

The score is counting real pressure here. One of these alone is routine; it’s the combination that makes this market worth watching.

  • in shortage now+25
  • Class I/II recall on same molecule/form in past 12 months+8
  • price down 29% year over year+8

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.2%chance of a new FDA shortage posting for lisdexamfetamine dimesylate (oral solid) in the next 90 days

7 Class I/II recall(s) in 12 months · OAI inspection at a producing facility (24 months) · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is 2× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Regulatory

Application
ANDA214547
TE code
AB
Approval date
Aug 25, 2023
Patents / exclusivity
None on file

Shortage history

  • In shortage now — Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 42858-167-01)Jan 11, 2024
    Shortage of an active ingredient
    month 32 — 2× the typical 14-month oral solid shortage · model puts 38% odds it resolves within 6 months
  • In shortage now — Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 60505-4739-1)Nov 1, 2023
    month 35 — 3× the typical 14-month oral solid shortage · model puts 38% odds it resolves within 6 months
  • In shortage now — Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 60505-4740-1)Nov 1, 2023
    Delay in shipping of the drug
    month 35 — 3× the typical 14-month oral solid shortage · model puts 38% odds it resolves within 6 months
  • In shortage now — Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 60505-4741-1)Nov 1, 2023
    month 35 — 3× the typical 14-month oral solid shortage · model puts 38% odds it resolves within 6 months
  • In shortage now — Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 60505-4742-1)Nov 1, 2023
    month 35 — 3× the typical 14-month oral solid shortage · model puts 38% odds it resolves within 6 months
  • In shortage now — Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 60505-4743-1)Nov 1, 2023
    Delay in shipping of the drug
    month 35 — 3× the typical 14-month oral solid shortage · model puts 38% odds it resolves within 6 months
  • In shortage now — Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 60505-4744-1)Nov 1, 2023
    month 35 — 3× the typical 14-month oral solid shortage · model puts 38% odds it resolves within 6 months
  • In shortage now — Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 60505-4745-1)Nov 1, 2023
    month 35 — 3× the typical 14-month oral solid shortage · model puts 38% odds it resolves within 6 months
  • In shortage now — Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0527-4666-37)Sep 20, 2023
    month 36 — 3× the typical 14-month oral solid shortage · model puts 38% odds it resolves within 6 months
  • In shortage now — Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0054-0660-25)Jul 14, 2023
    Shortage of an active ingredient
    month 38 — 3× the typical 14-month oral solid shortage · model puts 38% odds it resolves within 6 months
  • In shortage now — Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0406-5111-01)Jul 14, 2023
    month 38 — 3× the typical 14-month oral solid shortage · model puts 38% odds it resolves within 6 months
  • In shortage now — Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0480-3565-01)Jul 14, 2023
    month 38 — 3× the typical 14-month oral solid shortage · model puts 38% odds it resolves within 6 months
  • In shortage now — Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0527-4661-37)Jul 14, 2023
    month 38 — 3× the typical 14-month oral solid shortage · model puts 38% odds it resolves within 6 months
  • In shortage now — Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 42858-161-01)Jul 14, 2023
    month 38 — 3× the typical 14-month oral solid shortage · model puts 38% odds it resolves within 6 months
  • In shortage now — Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 47781-562-01)Jul 14, 2023
    month 38 — 3× the typical 14-month oral solid shortage · model puts 38% odds it resolves within 6 months
  • In shortage now — Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 57664-046-88)Jul 14, 2023
    Other
    month 38 — 3× the typical 14-month oral solid shortage · model puts 38% odds it resolves within 6 months
  • In shortage now — Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 64850-550-01)Jul 14, 2023
    Shortage of an active ingredient
    month 38 — 3× the typical 14-month oral solid shortage · model puts 38% odds it resolves within 6 months
  • In shortage now — Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0054-0370-25)Jul 14, 2023
    Shortage of an active ingredient
    month 38 — 3× the typical 14-month oral solid shortage · model puts 38% odds it resolves within 6 months
  • In shortage now — Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0406-5112-01)Jul 14, 2023
    month 38 — 3× the typical 14-month oral solid shortage · model puts 38% odds it resolves within 6 months
  • In shortage now — Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0480-3566-01)Jul 14, 2023
    month 38 — 3× the typical 14-month oral solid shortage · model puts 38% odds it resolves within 6 months

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of lisdexamfetamine dimesylate (Capsule)

LabelerStrengthFirst seenLast seen
Bryant Ranch PrepackLISDEXAMFETAMINE DIMESYLATE 30 mg/1Jul 15, 2026Sep 3, 2026
Alvogen Inc.LISDEXAMFETAMINE DIMESYLATE 40 mg/1Jul 15, 2026Sep 2, 2026
Alvogen Inc.LISDEXAMFETAMINE DIMESYLATE 60 mg/1Jul 15, 2026Sep 2, 2026
Alvogen Inc.LISDEXAMFETAMINE DIMESYLATE 70 mg/1Jul 15, 2026Sep 2, 2026
Alvogen Inc.LISDEXAMFETAMINE DIMESYLATE 20 mg/1Jul 15, 2026Sep 2, 2026
Alvogen Inc.LISDEXAMFETAMINE DIMESYLATE 10 mg/1Jul 15, 2026Sep 2, 2026
Alvogen Inc.LISDEXAMFETAMINE DIMESYLATE 50 mg/1Jul 15, 2026Sep 2, 2026
Alvogen Inc.LISDEXAMFETAMINE DIMESYLATE 30 mg/1Jul 15, 2026Sep 2, 2026
American Health PackagingLISDEXAMFETAMINE DIMESYLATE 50 mg/1Jul 15, 2026Sep 2, 2026
American Health PackagingLISDEXAMFETAMINE DIMESYLATE 70 mg/1Jul 15, 2026Sep 2, 2026
American Health PackagingLISDEXAMFETAMINE DIMESYLATE 60 mg/1Jul 15, 2026Sep 2, 2026
American Health PackagingLISDEXAMFETAMINE DIMESYLATE 20 mg/1Jul 15, 2026Sep 2, 2026
American Health PackagingLISDEXAMFETAMINE DIMESYLATE 30 mg/1Jul 15, 2026Sep 2, 2026
American Health PackagingLISDEXAMFETAMINE DIMESYLATE 40 mg/1Jul 15, 2026Sep 2, 2026
Apotex Corp.LISDEXAMFETAMINE DIMESYLATE 70 mg/1Jul 15, 2026Sep 2, 2026
Apotex Corp.LISDEXAMFETAMINE DIMESYLATE 50 mg/1Jul 15, 2026Sep 2, 2026
Apotex Corp.LISDEXAMFETAMINE DIMESYLATE 40 mg/1Jul 15, 2026Sep 2, 2026
Apotex Corp.LISDEXAMFETAMINE DIMESYLATE 10 mg/1Jul 15, 2026Sep 2, 2026
Apotex Corp.LISDEXAMFETAMINE DIMESYLATE 60 mg/1Jul 15, 2026Sep 2, 2026
Apotex Corp.LISDEXAMFETAMINE DIMESYLATE 30 mg/1Jul 15, 2026Sep 2, 2026
Apotex Corp.LISDEXAMFETAMINE DIMESYLATE 20 mg/1Jul 15, 2026Sep 2, 2026
Bryant Ranch PrepackLISDEXAMFETAMINE DIMESYLATE 60 mg/1Jul 15, 2026Sep 2, 2026
Bryant Ranch PrepackLISDEXAMFETAMINE DIMESYLATE 50 mg/1Jul 15, 2026Sep 2, 2026
Bryant Ranch PrepackLISDEXAMFETAMINE DIMESYLATE 70 mg/1Jul 15, 2026Sep 2, 2026
Bryant Ranch PrepackLISDEXAMFETAMINE DIMESYLATE 10 mg/1Jul 15, 2026Sep 2, 2026
Bryant Ranch PrepackLISDEXAMFETAMINE DIMESYLATE 40 mg/1Jul 15, 2026Sep 2, 2026
Bryant Ranch PrepackLISDEXAMFETAMINE DIMESYLATE 20 mg/1Jul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.LISDEXAMFETAMINE DIMESYLATE 40 mg/1Jul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.LISDEXAMFETAMINE DIMESYLATE 60 mg/1Jul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.LISDEXAMFETAMINE DIMESYLATE 50 mg/1Jul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.LISDEXAMFETAMINE DIMESYLATE 20 mg/1Jul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.LISDEXAMFETAMINE DIMESYLATE 30 mg/1Jul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.LISDEXAMFETAMINE DIMESYLATE 10 mg/1Jul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.LISDEXAMFETAMINE DIMESYLATE 70 mg/1Jul 15, 2026Sep 2, 2026
Elite Laboratories, Inc.LISDEXAMFETAMINE DIMESYLATE 10 mg/1Jul 15, 2026Sep 2, 2026
Elite Laboratories, Inc.LISDEXAMFETAMINE DIMESYLATE 40 mg/1Jul 15, 2026Sep 2, 2026
Elite Laboratories, Inc.LISDEXAMFETAMINE DIMESYLATE 50 mg/1Jul 15, 2026Sep 2, 2026
Elite Laboratories, Inc.LISDEXAMFETAMINE DIMESYLATE 20 mg/1Jul 15, 2026Sep 2, 2026
Elite Laboratories, Inc.LISDEXAMFETAMINE DIMESYLATE 30 mg/1Jul 15, 2026Sep 2, 2026
Elite Laboratories, Inc.LISDEXAMFETAMINE DIMESYLATE 60 mg/1Jul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "lisdexamfetamine dimesylate — NDC 47781-0565-01," retrieved September 3, 2026, https://drugdashboards.com/drug/47781056501.

Free to cite with attribution — see how the data is put together.